Abstract:USP21 belongs to the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs), which catalyze the removal of ubiquitin chain from targeted proteins. Numerous efforts over the last decade have identified a wide range of USP21 substrates and revealed the momentous and multifaceted role of USP21 in physiological and pathological states, especially in tumorigenesis, indicating that USP21 is an appealing target for the therapy of many correlative diseases. Nevertheless, progress in the development of potent USP21 inhibitors remains limited. Herein, we present the discovery of HSN003839, a highly potent and selective USP21 inhibitor with excellent anticancer activity and drug-like properties. Following screening tool compounds to identify hits and subsequent optimization, we discovered a series of compounds with strong enzymatic inhibition for USP21 with IC50 < 100 nM. Among them, HSN003839 displayed low nanomolar cancer cells proliferation inhibitions and excellent ADMET properties. The mouse oral bioavailability (F) is 76.5% at 10 mg/kg. In a preliminary mouse CDX model, monotherapy of HSN003839 showed 105% tumor growth inhibition (TGI) at 30 mg/kg with no obvious body weight reduction. Further biological characterization, efficacy and toxicity studies are ongoing. The structure of HSN003839 was not presented and will not be disclosed at the time of presentation at AACR meeting. Citation Format: Xiaohui Liu, Ying Wang, Dongliang Xia, Wei Zhang, Yan He, Shijie Tian, Xuerong Feng, Xia Yang, Qi Zhang, Fei Liu, Shiyi Jiang, Ran Hu, Ming Tang, Xuelin Tang, Yuqing Liu, Weijiao Yuan, Xuedan You. Discovery of HSN003839, a highly potent inhibitor of ubiquitin-specific protease USP21 for cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1835.

Discovery of N-Benzylpiperidinol derivatives as USP7 inhibitors against Hematology

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity

Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Discovery of Novel USP8 Inhibitors Via Ubiquitin-Rho-110 Fluorometric Assay Based High Throughput Screening.

The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364

Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of selective and potent USP22 inhibitors via structure-based virtual screening and bioassays exerting anti-tumor activity

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Virtual screening of natural products targeting ubiquitin-specific protease 7

Characterization of Naturally Occurring Pentacyclic Triterpenes As Novel Inhibitors of Deubiquitinating Protease USP7 with Anticancer Activity in Vitro

Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody

Discovery, Cocrystallization and Biological Evaluation of Novel Piperidine Derivatives As High Affinity Ls-AChBP Ligands Possessing Α7 Nachr Activities.

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Structure-based discovery of potent USP28 inhibitors derived from Vismodegib

Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines As Novel Bruton’s Tyrosine Kinase Inhibitors

Abstract 1835: Discovery of HSN003839, a highly potent inhibitor of ubiquitin-specific protease USP21 for cancer therapy